Home »
Academic Articles »
C »
A 9-mRNA signature measured from whole blood by a prototype PCR panel predicts 28-day mortality upon admission of critically ill COVID-19 patients
A 9-mRNA signature measured from whole blood by a prototype PCR panel predicts 28-day mortality upon admission of critically ill COVID-19 patients
Claire Tardiveau
(Joint Research Unit HCL-bioMérieux, Equipe d'Accueil (EA) 7426 “Pathophysiology of Injury-Induced Immunosuppression” (Université Claude Bernard Lyon 1 – Hospices Civils de Lyon, bioMérieux), Lyon, France)
Claire Tardiveau
(Open Innovation and Partnerships (OIP), bioMérieux Société Anonyme (S.A.), Lyon, France)
Guillaume Monneret
(Joint Research Unit HCL-bioMérieux, Equipe d'Accueil (EA) 7426 “Pathophysiology of Injury-Induced Immunosuppression” (Université Claude Bernard Lyon 1 – Hospices Civils de Lyon, bioMérieux), Lyon, France)
Guillaume Monneret
(Immunology Laboratory, Edouard Herriot Hospital – Hospices Civils de Lyon, Lyon, France)
Anne-Claire Lukaszewicz
(Joint Research Unit HCL-bioMérieux, Equipe d'Accueil (EA) 7426 “Pathophysiology of Injury-Induced Immunosuppression” (Université Claude Bernard Lyon 1 – Hospices Civils de Lyon, bioMérieux), Lyon, France)
Anne-Claire Lukaszewicz
(Anaesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France)
Valérie Cheynet
(Joint Research Unit HCL-bioMérieux, Equipe d'Accueil (EA) 7426 “Pathophysiology of Injury-Induced Immunosuppression” (Université Claude Bernard Lyon 1 – Hospices Civils de Lyon, bioMérieux), Lyon, France)
Valérie Cheynet
(Open Innovation and Partnerships (OIP), bioMérieux Société Anonyme (S.A.), Lyon, France)
Elisabeth Cerrato
(Joint Research Unit HCL-bioMérieux, Equipe d'Accueil (EA) 7426 “Pathophysiology of Injury-Induced Immunosuppression” (Université Claude Bernard Lyon 1 – Hospices Civils de Lyon, bioMérieux), Lyon, France)
Elisabeth Cerrato
(Open Innovation and Partnerships (OIP), bioMérieux Société Anonyme (S.A.), Lyon, France)
Katia Imhoff
(Joint Research Unit HCL-bioMérieux, Equipe d'Accueil (EA) 7426 “Pathophysiology of Injury-Induced Immunosuppression” (Université Claude Bernard Lyon 1 – Hospices Civils de Lyon, bioMérieux), Lyon, France)
Katia Imhoff
(Open Innovation and Partnerships (OIP), bioMérieux Société Anonyme (S.A.), Lyon, France)
Estelle Peronnet
(Joint Research Unit HCL-bioMérieux, Equipe d'Accueil (EA) 7426 “Pathophysiology of Injury-Induced Immunosuppression” (Université Claude Bernard Lyon 1 – Hospices Civils de Lyon, bioMérieux), Lyon, France)
Estelle Peronnet
(Open Innovation and Partnerships (OIP), bioMérieux Société Anonyme (S.A.), Lyon, France)
Maxime Bodinier
(Joint Research Unit HCL-bioMérieux, Equipe d'Accueil (EA) 7426 “Pathophysiology of Injury-Induced Immunosuppression” (Université Claude Bernard Lyon 1 – Hospices Civils de Lyon, bioMérieux), Lyon, France)
Maxime Bodinier
(Open Innovation and Partnerships (OIP), bioMérieux Société Anonyme (S.A.), Lyon, France)
Louis Kreitmann
(Joint Research Unit HCL-bioMérieux, Equipe d'Accueil (EA) 7426 “Pathophysiology of Injury-Induced Immunosuppression” (Université Claude Bernard Lyon 1 – Hospices Civils de Lyon, bioMérieux), Lyon, France)
Louis Kreitmann
(Open Innovation and Partnerships (OIP), bioMérieux Société Anonyme (S.A.), Lyon, France)
Sophie Blein
(Joint Research Unit HCL-bioMérieux, Equipe d'Accueil (EA) 7426 “Pathophysiology of Injury-Induced Immunosuppression” (Université Claude Bernard Lyon 1 – Hospices Civils de Lyon, bioMérieux), Lyon, France)
Sophie Blein
(Open Innovation and Partnerships (OIP), bioMérieux Société Anonyme (S.A.), Lyon, France)
Jean-François Llitjos
(Joint Research Unit HCL-bioMérieux, Equipe d'Accueil (EA) 7426 “Pathophysiology of Injury-Induced Immunosuppression” (Université Claude Bernard Lyon 1 – Hospices Civils de Lyon, bioMérieux), Lyon, France)
Jean-François Llitjos
(Open Innovation and Partnerships (OIP), bioMérieux Société Anonyme (S.A.), Lyon, France)
Jean-François Llitjos
(Anaesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France)
Filippo Conti
(Joint Research Unit HCL-bioMérieux, Equipe d'Accueil (EA) 7426 “Pathophysiology of Injury-Induced Immunosuppression” (Université Claude Bernard Lyon 1 – Hospices Civils de Lyon, bioMérieux), Lyon, France)
Filippo Conti
(Immunology Laboratory, Edouard Herriot Hospital – Hospices Civils de Lyon, Lyon, France)
Morgane Gossez
(Immunology Laboratory, Edouard Herriot Hospital – Hospices Civils de Lyon, Lyon, France)
Morgane Gossez
(Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS, UMR5308, Ecole Normale supérieure de Lyon, Université Claude Bernard-Lyon 1, Lyon, France)
Marielle Buisson
(Centre d’Investigation Clinique de Lyon (CIC 1407 Inserm), Hospices Civils de Lyon, Lyon, France)
Hodane Yonis
(Medical Intensive Care Department, Hospices Civils de Lyon, Croix-Rousse Hospital, Lyon, France)
Martin Cour
(Medical Intensive Care Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France)
Laurent Argaud
(Medical Intensive Care Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France)
Marie-Charlotte Delignette
(Anaesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Croix-Rousse Hospital, Lyon, France)
Florent Wallet
(0Medical Intensive Care Department, Hospices Civils de Lyon, Lyon sud Hospital, Pierre-Bénite, France)
Frederic Dailler
(1Neurological Anesthesiology and Intensive Care Department, Hospices Civils de Lyon, Pierre Wertheimer Hospital, Lyon, France)
Céline Monard
(Anaesthesia and Critical Care Medicine Department, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France)
Karen Brengel-Pesce
(Joint Research Unit HCL-bioMérieux, Equipe d'Accueil (EA) 7426 “Pathophysiology of Injury-Induced Immunosuppression” (Université Claude Bernard Lyon 1 – Hospices Civils de Lyon, bioMérieux), Lyon, France)
Karen Brengel-Pesce
(Open Innovation and Partnerships (OIP), bioMérieux Société Anonyme (S.A.), Lyon, France)
Fabienne Venet
(Immunology Laboratory, Edouard Herriot Hospital – Hospices Civils de Lyon, Lyon, France)
Fabienne Venet
(Centre International de Recherche en Infectiologie (CIRI), INSERM U1111, CNRS, UMR5308, Ecole Normale supérieure de Lyon, Université Claude Bernard-Lyon 1, Lyon, France)
the RICO study group
Journal: Frontiers in Immunology
•
• Frontiers Media S.A.
• ISSN: 1664-3224
Abstract
Immune responses affiliated with COVID-19 severity have been characterized and associated with deleterious outcomes. These approaches were mainly based on research tools not usable in routine clinical practice at the bedside. We observed that a multiplex transcriptomic panel prototype termed Immune Profiling Panel (IPP) could capture the dysregulation of immune responses of ICU COVID-19 patients at admission. Nine transcripts were associated with mortality in univariate analysis and this 9-mRNA signature remained significantly associated with mortality in a multivariate analysis that included age, SOFA and Charlson scores. Using a machine learning model with these 9 mRNA, we could predict the 28-day survival status with an Area Under the Receiver Operating Curve (AUROC) of 0.764. Interestingly, adding patients’ age to the model resulted in increased performance to predict the 28-day mortality (AUROC reaching 0.839). This prototype IPP demonstrated that such a tool, upon clinical/analytical validation and clearance by regulatory agencies could be used in clinical routine settings to quickly identify patients with higher risk of death requiring thus early aggressive intensive care.
Claire Tardiveau, Claire Tardiveau, Guillaume Monneret, et al. (2022). "A 9-mRNA signature measured from whole blood by a prototype PCR panel predicts 28-day mortality upon admission of critically ill COVID-19 patients". Frontiers in Immunology. https://doi.org/10.3389/fimmu.2022.1022750